18 th March 2016, Amsterdam, Netherlands. Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC â„¢ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results